140D042690034
Other Transaction Agreement
Overview
Government Description
Ai Abscopal System Planning & Immunogenic Radiotherapy With Nanocaflanone Theranostic (ASPIRANT)
Awardee
Awarding Agency
Funding Agency
NAICS
Not Reported
Place of Performance
Baltimore, MD 21202 United States
Pricing
Other
Set Aside
None
Extent Competed
Competed
Related Opportunity
None
Flavocure Biotech was awarded
Other Transaction Agreement 140D042690034 140D042690034
for AI ABSCOPAL System Planning & Immunogenic Radiotherapy with Nanocaflanone Theranostic (ASPI
worth up to $24,497,706
by the National Institutes of Health
in September 2026.
The contract
has a duration of 5 years and
was awarded
full & open
with
PSC AN13
via program solicitation acquisition procedures.
As of today, the Other Transaction Agreement has a total reported backlog of $13,365,793.
Status
(Open)
Last Modified 9/28/26
Period of Performance
9/25/26
Start Date
9/24/31
Current End Date
9/26/31
Potential End Date
Obligations and Backlog
$11.1M
Total Obligated
$11.1M
Current Award
$24.5M
Potential Award
$0.0
Funded Backlog
$13.4M
Total Backlog
Award Hierarchy
Other Transaction Agreement
140D042690034
Subcontracts
OTA Details
Type of Agreement
Prototype
Non-Governmental Funding
None Reported
Non-Traditional Participation
Non-Traditional Significant Participation
Activity Timeline
People
Suggested agency contacts for 140D042690034
Competition
Number of Bidders
Not Applicable
Solicitation Procedures
Program Solicitation
Evaluated Preference
None
Commercial Item Acquisition
None
Simplified Procedures for Commercial Items
None
Other Categorizations
Subcontracting Plan
Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Large Business
Awardee UEI
US4AMJMHHE85
Awardee CAGE
8F3Y7
Agency Detail
Awarding Office
140D04 IBC ACQ SVCS DIRECTORATE (00004)
Funding Office
75N992
Created By
decarloj
Last Modified By
decarloj
Approved By
decarloj
Legislative
Legislative Mandates
None Applicable
Performance District
MD-07
Senators
Benjamin Cardin
Chris Van Hollen
Chris Van Hollen
Representative
Kweisi Mfume
Modified: 9/28/26